Candace Patterson
A5079430523- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Genomics and Rare Diseases
- Bone fractures and treatments
- BRCA gene mutations in cancer
- Gene expression and cancer classification
- Scientific Computing and Data Management
- Genomic variations and chromosomal abnormalities
- Neuroendocrine Tumor Research Advances
- Monoclonal and Polyclonal Antibodies Research
- Bone health and treatments
- CRISPR and Genetic Engineering
- Cardiac Structural Anomalies and Repair
- Genetic Mapping and Diversity in Plants and Animals
- RNA modifications and cancer
- Ferroptosis and cancer prognosis
- Cardiac Valve Diseases and Treatments
- Cardiomyopathy and Myosin Studies
- Health Systems, Economic Evaluations, Quality of Life
- Ethics in Clinical Research
- Immunotoxicology and immune responses
- Genetics and Neurodevelopmental Disorders
Broad Institute
2019-2024
Massachusetts Institute of Technology
2020-2021
University of Dundee
1980
Polygenic risk scores (PRSs) have improved in predictive performance, but several challenges remain to be addressed before PRSs can implemented the clinic, including reduced performance of diverse populations, and interpretation communication genetic results both providers patients. To address these challenges, National Human Genome Research Institute-funded Electronic Medical Records Genomics (eMERGE) Network has developed a framework pipeline for return PRS-based genome-informed assessment...
Abstract Purpose: Sensitivity to endocrine therapy (ET) is critical for the clinical benefit from combination of palbociclib plus ET in hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer. Bazedoxifene a third-generation selective estrogen receptor (ER) modulator and ER degrader with activity preclinical models endocrine-resistant cancer, including harboring ESR1 mutations. Clinical trials healthy women showed that bazedoxifene well tolerated. Patients Methods: We...
Abstract The traditional model of genomic data analysis - downloading from centralized warehouses for with local computing resources is increasingly unsustainable. Not only are transfers slow and cost prohibitive, but this approach also leads to redundant siloed compute infrastructure that makes it difficult ensure security compliance protected data. NHGRI Genomic Data Science Analysis, Visualization, Informatics Lab-space (AnVIL; https://anvilproject.org ) inverts model, providing a unified...
Abstract Purpose: Whole-exome (WES) and RNA sequencing (RNA-seq) are key components of cancer immunogenomic analyses. To evaluate the consistency tumor WES RNA-seq profiling platforms across different centers, Cancer Immune Monitoring Analysis Centers (CIMAC) Immunologic Data Commons (CIDC) conducted a systematic harmonization study. Experimental Design: DNA were centrally extracted from fresh frozen formalin-fixed paraffin-embedded non–small cell lung carcinoma tumors distributed to three...
ABSTRACT Background As healthcare moves from a one-size-fits-all approach towards precision care, individual risk prediction is an important step in disease prevention and early detection. Biobank-linked systems can generate knowledge about genomic test the impact of implementing that care. Risk-stratified prostate cancer screening one clinical application might benefit such approach. Methods We developed translation pipeline for genomics-informed national system. used data 585,418 male...
<p>Supplementary tables 1-4 and supplementary figure legend</p>
<p>supplemental tables 5-7</p>
<p>Supplemental Figure 6: Evolutionary analysis of longitudinal plasma ctDNA samples</p>
<p>Supplemental Figure 3: Plasma circulating tumor DNA (ctDNA) fraction (TF) dynamics determined with ULP-WGS</p>
<p>Supplemental Figure 4: Overview of SSNVs in 68 ctDNA WES samples</p>
<p>Supplemental Figure 5: SSNVs detected in the cancer-related genes across 68 ctDNA WES samples</p>
<p>Supplemental Figure 2: Plasma circulating tumor DNA (ctDNA) collection and analysis</p>
<div>AbstractPurpose:<p>Sensitivity to endocrine therapy (ET) is critical for the clinical benefit from combination of palbociclib plus ET in hormone receptor–positive/HER2-negative (HR<sup>+</sup>/HER2<sup>−</sup>) advanced breast cancer. Bazedoxifene a third-generation selective estrogen receptor (ER) modulator and ER degrader with activity preclinical models endocrine-resistant cancer, including harboring <i>ESR1</i> mutations. Clinical...
<div>AbstractPurpose:<p>Sensitivity to endocrine therapy (ET) is critical for the clinical benefit from combination of palbociclib plus ET in hormone receptor–positive/HER2-negative (HR<sup>+</sup>/HER2<sup>−</sup>) advanced breast cancer. Bazedoxifene a third-generation selective estrogen receptor (ER) modulator and ER degrader with activity preclinical models endocrine-resistant cancer, including harboring <i>ESR1</i> mutations. Clinical...
<p>Supplemental Figure 1: Consort diagram</p>
<p>supplemental tables 5-7</p>
<p>Supplementary tables 1-4 and supplementary figure legend</p>
<p>Supplemental Figure 6: Evolutionary analysis of longitudinal plasma ctDNA samples</p>
<p>Supplemental Figure 5: SSNVs detected in the cancer-related genes across 68 ctDNA WES samples</p>
<p>Supplemental Figure 2: Plasma circulating tumor DNA (ctDNA) collection and analysis</p>
<p>Supplemental Figure 4: Overview of SSNVs in 68 ctDNA WES samples</p>
<p>Supplemental Figure 1: Consort diagram</p>